

Abby Li

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1867310/publications.pdf>

Version: 2024-02-01

28
papers

565
citations

566801

15
h-index

610482

24
g-index

28
all docs

28
docs citations

28
times ranked

628
citing authors

#	ARTICLE	IF	CITATIONS
1	Memantine in dementia: a review of the current evidence. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 787-800.	0.9	53
2	CARESS: The Canadian Registry of Palivizumab. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, 651-655.	1.1	44
3	Respiratory Syncytial Virus Prophylaxis in Down Syndrome: A Prospective Cohort Study. <i>Pediatrics</i> , 2014, 133, 1031-1037.	1.0	42
4	Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations. <i>European Journal of Pediatrics</i> , 2012, 171, 833-841.	1.3	37
5	Predictors of readmission to a psychiatry inpatient unit. <i>Comprehensive Psychiatry</i> , 2014, 55, 426-430.	1.5	36
6	Adherence to Palivizumab for Respiratory Syncytial Virus Prevention in the Canadian Registry of Palivizumab. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, e290-e297.	1.1	35
7	Respiratory-Related Hospitalizations following Prophylaxis in the Canadian Registry for Palivizumab (2005-2012) Compared to Other International Registries. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-15.	3.3	34
8	Does Pharmacological Treatment of Neuropsychiatric Symptoms in Alzheimer's Disease Relieve Caregiver Burden?. <i>Drugs and Aging</i> , 2012, 29, 167-179.	1.3	33
9	Adherence and outcomes: a systematic review of palivizumab utilization. <i>Expert Review of Respiratory Medicine</i> , 2018, 12, 27-42.	1.0	31
10	Outcomes of Infants Receiving Palivizumab Prophylaxis for Respiratory Syncytial Virus in Canada and Italy. <i>Pediatric Infectious Disease Journal</i> , 2017, 36, 2-8.	1.1	28
11	Discontinuing cholinesterase inhibitors: results of a survey of Canadian dementia experts. <i>International Psychogeriatrics</i> , 2011, 23, 539-545.	0.6	25
12	Hospitalization for Respiratory Syncytial Virus Illness in Down Syndrome Following Prophylaxis With Palivizumab. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, e29-e33.	1.1	25
13	A review of cost-effectiveness of palivizumab for respiratory syncytial virus. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2012, 12, 553-567.	0.7	20
14	Serious Adverse Events in the Canadian Registry of Children Receiving Palivizumab (CARESS) for Respiratory Syncytial Virus Prevention. <i>PLoS ONE</i> , 2015, 10, e0134711.	1.1	20
15	Are Vascular Risk Factors Associated With Post-Stroke Depressive Symptoms?. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2011, 24, 215-221.	1.2	18
16	Comparing First- and Second-year Palivizumab Prophylaxis in Patients With Hemodynamically Significant Congenital Heart Disease in the CARESS Database (2005-2015). <i>Pediatric Infectious Disease Journal</i> , 2017, 36, 445-450.	1.1	15
17	Antidepressant-placebo differences for specific adverse events in major depressive disorder: A systematic review. <i>Journal of Affective Disorders</i> , 2020, 267, 185-190.	2.0	13
18	First versus second year respiratory syncytial virus prophylaxis in chronic lung disease (2005-2015). <i>European Journal of Pediatrics</i> , 2017, 176, 413-422.	1.3	12

#	ARTICLE	IF	CITATIONS
19	Palivizumab prophylaxis for respiratory syncytial virus in infants with cystic fibrosis: is there a need?. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018, 37, 1113-1118.	1.3	8
20	Cost-analysis of Withdrawing Immunoprophylaxis for Respiratory Syncytial Virus in Infants Born at 33-35 Weeks Gestational Age in Quebec. <i>Pediatric Infectious Disease Journal</i> , 2020, 39, 694-699.	1.1	8
21	Respiratory Syncytial Virus Immunoprophylaxis with Palivizumab: 12-Year Observational Study of Usage and Outcomes in Canada. <i>American Journal of Perinatology</i> , 2022, 39, 1668-1677.	0.6	8
22	Respiratory Syncytial Virus Prophylaxis in Immunocompromised Children. <i>Pediatric Infectious Disease Journal</i> , 2020, 39, 539-545.	1.1	7
23	Respiratory Syncytial Virus Prophylaxis in Neurologic and Muscular Disorders in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab. <i>Pediatric Infectious Disease Journal</i> , 2019, 38, 775-780.	1.1	6
24	CARESS. <i>Pediatric Infectious Disease Journal</i> , 2012, 31, 213.	1.1	3
25	Palivizumab Adherence and Outcomes in Canadian Aboriginal Children. <i>Pediatric Infectious Disease Journal</i> , 2016, 35, 1187-1193.	1.1	3
26	What risk factors for sudden infant death syndrome are preterm and term medically complex infants exposed to at home?. <i>Paediatrics and Child Health</i> , 2021, 26, e184-e188.	0.3	1
27	72 Use of Palivizumab in Canada; Data from the CARESS registry 2005-2017. <i>Paediatrics and Child Health</i> , 2019, 24, e28-e28.	0.3	0
28	A Comparison of Respiratory Syncytial Viral Prophylaxis in Multiple Births versus Singletons in the Canadian Registry of Palivizumab. <i>American Journal of Perinatology</i> , 2020, 38, e129-e136.	0.6	0